New Sucampo Amitiza launch squeezes $10m milestone out of Takeda
This article was originally published in Scrip
Executive Summary
Maryland, US-based biopharmaceutical company, Sucampo Pharmaceuticals has received a $10m milestone payment from its collaborative partner, Takeda Pharmaceutical on the launch of Amitiza in the US for another indication.